Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient ...

Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...

Biomarkers such as ring sideroblasts are indicators for response to treatments like luspatercept (Reblozyl). In patients with ...

While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...

Sonrotoclax has received FDA priority review for relapsed or refractory mantle cell lymphoma, indicating potential substantial treatment improvement. The BGB-11417-201 study demonstrated significant ...

The FDA has approved durvalumab (Imfinzi) plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for the treatment ...

RP1 and nivolumab combination achieved a 32.9% objective response rate and 15.0% complete response rate in advanced melanoma ...

Benjamin George, MD, has significantly improved cancer care access in rural Nebraska, Colorado, and Kansas, transforming ...

The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and ...

Lifileucel showed a 31.4% objective response rate and a median duration of response of 36.5 months in advanced melanoma patients. The median overall survival was 13.9 months, with adverse events ...